This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Estimates of effectiveness and key assumptions
The recurrence rate for UAE was assumed to be zero. It was assumed that patients who were not cured with UAE or hysterectomy had a postoperative quality of life similar to that before treatment, when menorrhagic. Although after hysterectomy uncured patients no longer had menorrhagia, the effect of their symptoms on their quality of life was assumed to be similar to that of menorrhagia. The utilities for the cured state after UAE were assumed to be similar to those of women in the same age group in the general population. It was assumed that the quality of life values were reduced by 20% for the duration of the recovery (post-procedural) period. This was 1 week for UAE and 6 weeks for hysterectomy. Major complications were also assumed to reduce quality of life by 20% during the additional time required to recover from them.
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-years (QALYs). The benefits were discounted at an annual rate of 3%.
Direct costs
It was stated that a societal perspective was adopted in the study. The direct costs included procedural costs and mortality costs. The procedural costs covered the hospital and physician, the treatment of complications, follow-up visits, and follow-up magnetic resonance imaging for patients who had undergone UAE. The mortality costs were assumed to be 150% of the procedural costs. The costs and the quantities were not reported separately. The data were obtained from the 1999 Medicare Provider Analysis and Review database. Additional information, used in the sensitivity analysis, was obtained from a hospital's accounting database, which calculated relative value units to represent both the technical difficulty costs and the time costs associated with the procedures. The total costs associated with the interventions evaluated were derived using modelling. The costs were discounted at an annual rate of 3% since they were incurred during 11 years. All the costs were converted to 1999 prices using the medical component of the consumer price index.
Statistical analysis of costs
The costs were treated deterministically. No statistical analysis of the costs was carried out.
Indirect Costs
The indirect costs reflected lost patient time due to recovery, complications and follow-up. The quantities and the costs were reported separately. Estimates of time lost were based on assumptions. Median weekly wage rates were adopted from the US Bureau of Labor Statistics for 2001. Productivity losses for patients who were not cured after treatment were based on the National Health Interview Survey, 1996. The total indirect costs were derived using modelling. The costs were incurred during 11 years and were therefore discounted at an annual rate of 3%. 1999 prices were used.
Currency

US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were performed. These tested the robustness of the results under a range of model assumptions, uncertain model transition probabilities and estimated costs. The parameters used were all transition probabilities of events following UAE or hysterectomy, recovery time, procedural costs, mortality costs, health-related quality of life weights, including no quality adjustments, mean age of cohort at the time of procedure, mean age at start of menopause, and discount rate. A wide range of values was used. These were based on expert opinion, alternative sources of cost data, and different assumptions on the model structure. No justification was provided for the ranges of some values, for example, those related to events following the procedures (e.g. mortality, complication and cure rates). A two-way sensitivity analysis was performed by simultaneously varying the utilities of cured patients after UAE and after hysterectomy.
Synthesis of costs and benefits
The costs and benefits were combined in the form of incremental cost-effectiveness ratios (ICERs). In the case of a strategy being more effective and less costly than its comparator (dominant strategy), the ICER was not calculated as this was unnecessary. ICERs expressed the additional costs per QALY gained. UAE dominated hysterectomy as it was both less expensive and more effective. The ICER of UAE compared with no treatment was $2,007 per QALY gained.
From the sensitivity analysis, the results were robust to changes in most model assumptions. UAE dominated hysterectomy in most scenarios. The exceptions were reducing the cure rate of UAE, increasing the procedural costs of UAE, increasing the recovery time following UAE, and reducing the recovery time following hysterectomy. All of these scenarios resulted in UAE being still more effective, but also more expensive, than hysterectomy. The ICER ranged from $1,771 to $15,940 per QALY gained. In addition, the results were sensitive to changes in the utilities for cure following treatment. When utilities for cure following UAE decreased or for cure following hysterectomy increased, then hysterectomy became more effective. With the elimination of the quality of life adjustments, UAE and hysterectomy became equally effective. Compared with no treatment, the maximum ICER of UAE was found to be $15,285 per QALY, after the whole range of values was examined in one-way analysis. Across most model assumptions UAE was more effective and more expensive than no treatment. There were two exceptions. Reducing the mean age of the patient cohort to 30 years resulted in no treatment being more expensive than UAE (UAE was therefore dominated in this case). Moreover, eliminating the quality of life adjustment made no treatment more effective than UAE.
The two-way sensitivity analysis showed that, if utilities for cure following UAE were reduced and those for cure following hysterectomy were increased, then hysterectomy became more effective and had an ICER that did not exceed $75,000 per QALY.
